{"groups":[{"description":"Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"FG000","title":"Lenvatinib"},{"description":"Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"FG001","title":"Sorafenib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"415"},{"groupId":"FG001","numSubjects":"402"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"12"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"10"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"52"}],"type":"Sponsor Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"478"},{"groupId":"FG001","numSubjects":"476"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"476"},{"groupId":"FG001","numSubjects":"475"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"478"},{"groupId":"FG001","numSubjects":"476"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 1,492 participants were screened, 954 participants were enrolled and randomized, out of which 951 participants were treated in the study.","recruitmentDetails":"Participants took part in the study at 154 investigative sites in Australia, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, South Korea, Malaysia, Philippines, Poland, Russia, Singapore, Spain, Taiwan, Thailand, United Kingdom, and the United States from 1 March 2013 to 10 March 2021."}